Biotech

BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug

After axing its lead obesity asset, BioAge has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses

Will Maddox May 14, 2026 11:00am

Fierce Biotech Fundraising Tracker '26: Create Medicines & more

May 14, 2026 10:45am

Setting a new standard in prefillable syringe systems

Brought to you by West Pharmaceutical Services, Inc.

Create Medicines fashions $122M raise for in vivo CAR-T dreams

May 14, 2026 9:42am

MRD as a Decision Engine: Rethinking Oncology Trial Design

Brought to you by Syneos Health

positive negative up down good bad mixed

Biogen advances Alzheimer’s tau program despite midphase miss

May 14, 2026 8:35am